Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer Over-expressing the c-Met Protein.

Next Previous
X
Search
Trial Profile

A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer Over-expressing the c-Met Protein.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ARGX 111 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors argenx

    • Most Recent Events

    • 07 Jul 2017 Results published in an Argenx media release.
    • 07 Jul 2017 According to an Argenx media release, abstract covering the complete data set from this trial was presented at American Society of Clinical Oncology (ASCO) program at the 3rd Singapore Society of Oncology Annual Scientific Meeting.
    • 02 May 2017 According to an Argenx media release, complete data set from this trial will be presented at the American Society of Clinical Oncology (ASCO) conference (Singapore) in July 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top